|
Vorasidenib Clinical Trials
3 actively recruiting trials across 1 location
Also known as: AG-881, S095032
Pipeline
Phase 1: 1Phase 3: 1
Top Sponsors
- iOMEDICO AG1
- Institut de Recherches Internationales Servier1
- European Organisation for Research and Treatment of Cancer - EORTC1
Indications
- Cancer3
- IDH-mutant Grade 2 or 3 Astrocytoma1
- Oligodendroglioma1
- Astrocytoma1
- Glioma1
Other2 trials
Birmingham, Alabama1 trial
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
University of Alabama at Birmingham
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.